8-K: DURECT Corporation Announces Positive Phase 2b Trial Results and Business Update

DURECT Corporation reports positive Phase 2b trial results for Larsucosterol in alcohol-associated hepatitis (AH) and provides a business update, including the sale of the ALZET product line.

Summary

• DURECT Corporation announced its fourth quarter and full year 2024 financial results and provided a business update on March 26, 2025.
• The company is planning a Phase 3 trial to evaluate larsucosterol for severe AH, with topline results expected within two years of trial initiation, contingent on securing sufficient funding.
• Results from the AHFIRM Phase 2b trial were published in NEJM Evidence in January 2025.
• In November 2024, DURECT sold its ALZET line of osmotic pumps to Lafayette Instrument Co. for $17.5 million and used the proceeds to repay its term loan.
• Total revenues for the fourth quarter of 2024 were $0.5 million, with a net income of $7.8 million, compared to $0.9 million in revenues and a net loss of $1.4 million for the same period in 2023.
• For the full year 2024, total revenues were $2.0 million, with a net loss of $7.9 million, compared to $2.6 million in revenues and a net loss of $27.6 million for the full year 2023.
• As of December 31, 2024, cash, cash equivalents, and investments totaled $12.0 million, compared to $29.8 million at the end of 2023.

Sentiment

Score: 7

Explanation: The sentiment is cautiously optimistic. Positive Phase 2b trial results and the ALZET sale are encouraging, but the need for additional funding for the Phase 3 trial introduces uncertainty.

Positives

• Publication of Phase 2b AHFIRM trial results in NEJM Evidence validates the potential of larsucosterol.
• Sale of the ALZET product line strengthened the balance sheet and allowed for the repayment of the term loan.
• Net loss decreased significantly from $27.6 million in 2023 to $7.9 million in 2024.
• Net income for the three months ended December 31, 2024 was $7.8 million compared to net loss of $1.4 million for the three months ended December 31, 2023.

Negatives

• Cash, cash equivalents, and investments decreased from $29.8 million at the end of 2023 to $12.0 million as of December 31, 2024.
• The Phase 3 trial is contingent on securing sufficient funding.
• Total revenues decreased from $2.6 million in 2023 to $2.0 million in 2024.

Risks

• The Phase 3 clinical trial of larsucosterol may be delayed or not confirm the results from the AHFIRM trial.
• DURECT may not be able to raise sufficient capital to commence or complete the Phase 3 clinical trial.
• The FDA may require additional clinical trials for larsucosterol before approving it for the treatment of AH.
• Breakthrough Therapy designation does not guarantee expedited FDA approval.
• DURECT's ability to continue to operate as a going concern is a risk.

Future Outlook

DURECT plans to initiate a Phase 3 trial of larsucosterol for severe AH in 2025, contingent on securing sufficient funding, with topline results expected within two years of trial initiation. The company is exploring all options for funding, including potential business development and financing transactions.

Management Comments

• We recently achieved significant accomplishments that reinforced our plans for continuing development of larsucosterol for AH and strengthened our balance sheet, stated James E. Brown, D.V.M., President and CEO of DURECT.
• We are excited that NEJM Evidence published the results of our Phase 2b AHFIRM trial in January 2025.
• Our primary focus continues to be initiating the Phase 3 trial of larsucosterol for severe AH, contingent on securing sufficient funding.
• We are engaged in active dialogue to explore all options for funding the continued development of larsucosterol, including potential business development and financing transactions.

Industry Context

The development of larsucosterol targets a significant unmet need in the treatment of alcohol-associated hepatitis (AH), for which there are currently no FDA-approved therapies. The high mortality rates associated with AH underscore the importance of developing effective treatments.

Comparison to Industry Standards

• The reported mortality rates for AH patients are approximately 20% at 28 days and 31% at 90 days, highlighting the severity of the condition.
• Current treatments, such as corticosteroids, have limitations and have not been shown to improve survival at 90 days or one year.
• Liver transplantation is an option, but it is limited by organ availability and high costs, with average charges exceeding $875,000.

Stakeholder Impact

• Shareholders: Potential for increased value if larsucosterol is successfully developed and approved.
• Employees: Job security and potential for growth within the company.
• Patients: Access to a potentially life-saving treatment for AH.
• Suppliers: Continued business relationships with DURECT.
• Creditors: Improved financial stability of DURECT.

Next Steps

• Initiate a Phase 3 clinical trial of larsucosterol for severe AH, contingent on securing sufficient funding.
• Continue exploring options for funding the development of larsucosterol.
• File the annual report on Form 10-K for the year ended December 31, 2024.

Key Dates

Keywords

Larsucosterol, Alcohol-associated hepatitis, AH, DURECT Corporation, AHFIRM trial, Phase 3 trial, ALZET, Financial results, Epigenetic therapies